Abciximab is one of the glycoprotein IIb/IIIa receptor inhibitors, and it is known to be effective for preventing and treating the thrombotic complications of percutaneous coronary intervention (PCI). On the other hand, there -in-duced thrombocytopenia. Acute profound thrombocytopenia is a rare, but life threatening adverse reaction to abciximab, and it can even ocur within a few hours of the first exposure. We report here on a case of 56 year-old woman who experienced masive bleeding of her brachial artery acces site. This was caused by abciximab-in-duced acute profound thrombocytopenia after performing PCI concomitant with using abciximab.